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J a n u a r y 22, 2019

Michele Lum bert, C lerk
K ennebec C ounty S u p e rio r C ourt
C apital Ju d ic ia l C en ter
1 C o u rt Street, S uite 101
A ugusta, ME 04330
Re:

S tate of M aine v. M edical Device B u sin e ss Services, Inc., et al.

D ear Ms. Lum bert:
E nclosed for filing in th e above-referenced m a tte r are a C om plaint
S u m m aiy Sheet; a C om plaint; a n d a C o n se n t J u d g m e n t for th e C o u rt’s
review a n d approval.
T h an k you for y o u r assista n ce .
Sincerely,

CAROLYN A. SILSBY
A s sista n t A ttorney G eneral
C A S /cs
E n clo su res
Ja m ee s M. C am pbell, Esq.
cc:
Jam
Ross B. G alin, E sq.

SUMMARY SHEET
M.R. Civ. P. 5(h)
This summary sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as
required by the Maine Rules of Court or by law. This form is required for the use of the Clerk of Court for the purpose of initiating or updating
the civil docket. (SEE ATTACHED INSTRUCTIONS)_________________________________________________________________________
I. County of Filing or District Court Jurisdiction: ¡^gpnqg^gQ
IX. CAUSE OF ACTION (Cite the primary civil statutes under which you are filing, if any.)

5 M.R.S. §§ 207 & 209

in.

NATURE OF FILING
H Initial Complaint
□ Third-Party Complaint
□ Cross-Claim or Counterclaim

C l If Reinstated or Reopened case, give original Docket Number
(If filing a second or subsequent Money Judgment Disclosure, give docket number o f first disclosure)
IV.

□ TITLE TO REAL ESTATE IS INVOLVED

V.

MOST DEFINITIVE NATURE OF ACTION. (Place an X in one box only)

□
□
□
□
□
□
□

□
□
□
□
□

Personal Injury Tort
Property Negligence
Auto Negligence
Medical Malpractice
Product Liability
Assault/Battery
Domestic Torts
Other Negligence
Other Personal Injury Tort
Non-Personal Injury Tort
Libel/Defamation
Auto Negligence
Other Negligence
Other Non-Personal Injury Tort

□
□
□
□

□
B

□

□

□

GENERAL CIVIL fCV)
Contract
Contract
Declaratory/Equitable Relief
General Injunctive Relief
Declaratory Judgment
Other Equitable Relief
Const]tutional/Civil Rights
Constitutional/Civil Rights
Statutory Actions
Unfair Trade Practices
Freedom of Access
Other Statutory Actions
Miscellaneous Civil
Drug Forfeitures

CHILD PROTECTIVE CUSTODY (PC)

Check the box that most closely describes your case.

□
□
□
□
□
□
□
□
□
□
□
□
□
□

Other Forfeitures/Property Libels
Land Use Enforcement (80K)
Administrative Warrant
HIV Testing
Arbitration Awards
Appointment of Receiver
Shareholders' Derivative Actions
Foreign Deposition
Pre-action Discovery
Common Law Habeas Coipus
Prisoner Transfers
Foreign Judgments
Minor Settlements
Other Civil

SPECIAL ACTIONS (SA)
Money Judgment
□
Money Judgment Request Disclosure

□

Non-DHS Protective Custody

□
□
□
□

Title Actions
Quiet Title
Eminent Domain
Easements
Boundaries

□
□

□

Governmental Body (SOB)

□

□

REAL ESTATE (RE1
Foreclosure
Foreclosure (ADR exempt)
Foreclosure (Diversion eligible)
Foreclosure - Other

Misc. Real Estate

□ Equitable Remedies
□ Mechanics Lien
□ Partition

□

Adverse Possession

□
□
□
□

Nuisance
Abandoned Roads
Trespass
Other Real Estate

APPEALS (AP) (To be filed in Superior Court) (ADR exempt)
Administrative Agency C80C)
_________ □ _ Other Appeals

VI. M.R. Civ. P. 16B Alternative Dispute Resolution (ADR):
■ I certify that pursuant to M.R. Civ. P. 16B(b), this case is exempt from a required ADR process because:
□ It falls within an exemption listed above (i.e., an appeal or an action for non-payment of a note in a secured transaction).
□ The plaintiff or defendant is incarcerated in a local, state or federal facility.
□ The parties have participated in a statutory pre-litigation screening process w ith _________________________________________
[H The parties have participated in a formal ADR process w ith_____________________________________________________ on
(date).
□ This is an action in which the plaintiff s likely damages will not exceed $50,000, and the plaintiff requests an exemption
from ADR pursuant to M.R. Civ. P. 16C(g).

gj This action has been settled by the parties per the proposed Consent Judgment
------ which has been filed-wi-th the "Complaint----------------------------------------
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VII. ( a ) H PLAINTIFFS (Name & Address including county)
or □ Third-Party, Cl Counterclaim or Cross-Claim Plaintiffs
□ The plaintiff is a prisoner in a local, state or federal facility.

State of Maine
Attorney General Aaron M. Frey
Office of the Attorney General
6 State House Station
Augusta, Maine 04333

(b) Attorneys (Name, Bar number, Firm name, Address, Telephone Number) If all counsel listed do NOT represent all plaintiffs,
specify who the listed attorney(s) represent.

Carolyn A. Silsby, ME Bar No. 3030
Assistant Attorney General
Office of the Attorney General
6 State House Station
Augusta, Maine 04333-0006
207-626-8800 / caroiyn.silsby@maine.gov

Hi

v m . (a)
DEFENDANTS (Name & Address including county)
and/or CH Third-Party, CH Counterclaim or □ Cross-Claim Defendants
□ The defendant is a prisoner in a local, state or federal facility.

1) Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NH 08933
2) Medical Device Business Services, Inc.
700 Orthopaedic Drive
Warsaw, IN 46582

3) DePuy Products, Inc.
700 Orthopaedic Drive
Warsaw, IN 46582
4) DePuy Synthes, Inc.
700 Orthopaedic Drive
Warsaw, IN 46582

5) DePuy Synthes Sales, Inc.
325 Paramount Drive
Raynham, MA 02767

If all counsel listed do NOT represent all defendants,
specify who the listed attorney(s) represents.

(b) Attorneys (Name, Bar number, Firm name, Address, Telephone Number)
(If known)

James M. Campbell, ME Bar No. 3551
Campbell, Conroy & O'Neil, P.C.
1 Constitutional Wharf, Suite 310
Boston, MA 02129
617-241-3000
jmcampbell@campbell-trial.lawyers.com
IX. (a)

CH PARTIES OF INTEREST (Name & Address including county)

If all counsel listed do NOT represent all parties,
specify who the listed attorney(s) represents.

(b) Attorneys (Name, Bar number, Firm name, Address, Telephone Number)
(If known)

X.

RELATED CASE(S) IF ANY.
Assigned Judge/Justice_______

Docket Number

-2,Z"
Date: Janauryy7 2019
N agé of P lain t^ ^ r Lead^ttt^hey ^Record
Signature of Plaintiff or Attorney
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SUPERIOR COURT
CIVIL ACTION
Docket No. CV-19-

STATE OF MAINE
KENNEBEC, ss.

STATE OF MAINE,
Plaintiff

y.
MEDICAL DEVICE BUSINESS SERVICES,
INC., F/K/A DEPUY INC., DEPUY
ORTHOPAEDICS, INC., AND DEPUY
ORTHOPAEDICS, INC.; DEPUY PRODUCTS,
INC.; DEPUY SYNTHES, INC.; DEPUY
SYNTHES SALES, INC.; AND JOHNSON
& JOHNSON,
Defendants

1.

)
)
)
)
)
)
)
)
)
)
)
)
)
)
)

COMPLAINT
(Injunctive Relief
Requested)

Plaintiff, State of Maine, brings this action, by and through its Attorney General,

against Defendants Medical Device Business Services, Inc., f/k/a DePuy Inc., DePuy Orthopaedics,
Inc., and DePuy Orthopaedics, Inc.; DePuy Products, Inc.; DePuy Synthes, Inc.; DePuy Synthes
Sales, Inc. (collectively referred to as “DePuy”); and Johnson & Johnson for violating 5 M.R.S.
§ 207 of the Maine Unfair Trade Practices Act (the “UTPA,” 5 M.R.S. §§ 205-A through 214).
PARTIES

2.

Plaintiff State of Maine (the “State”), brings this action, by and through its Attorney

General Aaron M. Frey in the public interest, pursuant to authority granted him by 5 M.R.S. § 209.
3.

Defendant Johnson & Johnson is a New Jersey company whose principal place of

business and executive offices are located at One Johnson & Johnson Plaza, New Brunswick, New
Jersey 08933.

4.

Defendant Medical Device Business Services, Inc., f/k/a DePuy Inc., DePuy

Orthopaedics, Inc., and DePuy Orthopaedics, Inc., is an Indiana company whose principal place
of business and executive offices are located at 700 Orthopaedic Drive, Warsaw, Indiana 46582.
5.

Defendant DePuy Products, Inc. is an Indiana company whose principal place of

business and executive offices are located at 700 Orthopaedic Drive, Warsaw, Indiana 46582.
6.

Defendant DePuy Synthes, Inc. is a Delaware company whose principal place of

business and executive offices are located at 700 Orthopaedic Drive, Warsaw, Indiana 46582.
7.

Defendant DePuy Synthes Sales, Inc. is a Massachusetts company whose

principal place of business and executive offices are located at 325 Paramount Drive, Raynham,
Massachusetts 02767.
8.

DePuy transacts business in Maine and nationwide by manufacturing, marketing,

promoting, advertising, offering for sale, and selling, prosthetic hip implant devices.
JURISDICTION AND VENUE

9.

This Court has subject matter jurisdiction over this matter pursuant to 4 M.R.S. § 105

and 5 M.R.S. § 209. This Court has jurisdiction over Defendants pursuant to 14 M.R.S. § 704A(2)(A) because Defendants have transacted business within the State of Maine at all times relevant
to this Complaint.
10.

Venue for this action properly lies in Kennebec County pursuant to 5 M.R.S. § 209.
TRADE AND COMMERCE

11.

DePuy was, at all times relevant hereto, engaged in trade or commerce in the State of

Maine as defined in 5 M.R.S. § 206(3).
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ALLEGATIONS

12.

The hip is a ball and socket joint with the head of the femur (ball) fitting into the

acetabulum (hip socket) of the pelvis. DePuy marketed metal-on-metal hip devices, including the
ASR XL and Pinnacle Ultamet. Beginning in 2005, DePuy marketed its ASR XL as a device that
would be appropriate for relatively younger, more active patients.
13.

As early as 2007, DePuy was aware that it was necessary to implant the ASR XL at a

precise acute angle, but that it was difficult for orthopedic surgeons to implant the devices at such a
precise angle consistently. Because the ASR XL had a comparatively large femoral head, it was
especially important to implant the cup at an angle of less than 45 degrees to avoid excessive wear.
Beginning in 2006, DePuy received complaints that the ASR cups, which were implanted into the
acetabulum of the pelvis, became loose resulting in premature failure.
14.

Even though DePuy was aware that its implants became loose, DePuy continued to

market the device as having stability and advanced fixation, citing survivorship of 99.2% at three
years in its “Never Stop Moving” marketing campaign. In 2009, DePuy learned that the National
Joint Registry of England and Wales reported a 7% revision rate at three years, but the company
continued to market the ASR XL using its “Advanced Stability and Low Wear” message. As the
ASR XL failed, consumers required new implantations and experienced persistent groin pain,
allergy, and tissue necrosis. On revision, surgeons found metal debris in the surrounding tissue and
some patients experienced increased levels of metal ions in their blood following implantation with
the ASR XL.
15.

In August 2010, DePuy voluntarily recalled the ASR XL because of the number of

patients requiring revision surgery.
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16.

The Pinnacle implant system is a hip implantation system that permitted the surgeon

to choose to implant a ceramic, polyethelene, or metal cup liner to interface with the metal femoral
head of the metal taper implanted in the femur. Pinnacle Ultamet was the metal cup liner device that
DePuy marketed to provide a metal-on-metal hip implant using the Pinnacle platform. Beginning in
2007, DePuy advertised that its Pinnacle Ultamet hip implant device had 99.8% survivorship at five
years based on a 2007 study that DePuy designed. DePuy continued to promote its devices as
having 99.8% and 99.9% survivorship at five years, even though the National Joint Registry of
England and Wales reported a 2.2% 3-year-revision rate in 2009, increasing to a 4.28% 5-yearrevision rate revision rate in 2012.
17.

DePuy ceased marketing and selling the Pinnacle Ultamet in 2013.
VIOLATIONS OF 5 M.R.S. § 207
MAINE UNFAIR TRADE PRACTICES ACT
Count One

18.

Plaintiff realleges and incorporates by reference herein each allegation contained in

the preceding paragraphs 1 through 17.
19.

DePuy, in the course of marketing, promoting, selling, and distributing its metal-on-

metal hip implants, has engaged in a course of trade or commerce which constitutes false, deceptive,
or misleading acts or practices, in violation of § 207 of the UTPA, including, but not limited to,
representing that goods or services had sponsorship, approval, characteristics, benefits, or qualities
that they did not have. DePuy violated § 207 of the UTPA when it misrepresented the sponsorship,
approval, characteristics, benefits or qualities of its metal-on-metal hip implant devices.
Count Two

20.

Plaintiff realleges and incorporates by reference herein each allegation contained in

the preceding paragraphs 1 through 17.
4

21.

DePuy, in the course of marketing, promoting, selling, and distributing its metal-on-

metal hip implants, has engaged in a course of trade or commerce which constitutes false, deceptive,
or misleading acts or practices, in violation of § 207 of the UTPA, including, but not limited to,
misrepresenting the failure rate of ASR XL and Pinnacle Ultamet metal-on-metal hip implant
devices.
PRAYER FOR RELIEF

WHEREFORE, the State respectfully requests that this Court:
A.

Declare that Defendants have violated 5 M.R.S. § 207 by making representations that

were deceptive or misleading in marketing, promoting, selling, and distribution their metal-on-metal
hip implants;
B.

Pursuant to 5 M.R.S. § 209, permanently enjoin and restrain Defendants, their agents,

employees, and all other persons and entities, corporate or otherwise, in active concert or
participation with any of them, Lorn engaging in false, misleading, or deceptive practices in the
marketing, promotion, selling, and distributing of their hip implant devices;
C.

Pursuant to 5 M.R.S. § 209, order Defendants to pay a civil of up to $10,000 for each

intentional violation of 5 M.R.S. § 207;
D.

Pursuant to 5 M.R.S. § 209 and 14 M.R.S. § 1522(A), order Defendants to pay the

Attorney General’s costs of investigation and reasonable attorneys’ fees incurred by the State in
connection with this matter; and
E.

Grant such further relief as the Court deems necessary or appropriate to remedy the

effects of Defendants’ unlawful trade practices.

5

Dated: January 22, 2019

Respectfully submitted,
AARON M. FREY
ATTORNEY GENERAL

/• I S S iS U U lL ¿ \ l l V L l L t y \J C U C l f c t i

Office of the Attorney General
6 State House Station
Augusta, ME 04333-0006
(207)626-8800
Carolyn.silsby@maine.gov
Counsel for Plaintiff
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SUPERIOR COURT
CIVIL ACTION
Docket No. CV-19- \P)

STATE OF MAINE
KENNEBEC, ss.

STATE OF MAINE,

)

)
Plaintiff

)

)
)

V.

CONSENT JUDGMENT

)
MEDICAL DEVICE BUSINESS SERVICES,
INC., F/K/A DEPUY INC., DEPUY ORTHOPEDICS,
INC., AND DEPUY
ORTHOPAEDICS, INC.; DEPUY PRODUCTS,
INC.; DEPUY SYNTHES, INC.; DEPUY
SYNTHES SALES, INC.; AND JOHNSON
& JOHNSON,

)
)
)
)
)
)
)

)
Defendants

)

Plaintiff, State of Maine, acting by and through its Attorney General Aaron M. Frey, has
brought this action against Medical Device Business Services, Inc., f/k/a DePuy Inc., DePuy
Orthopedics, Inc., and DePuy Orthopaedics, Inc.; DePuy Products, Inc.; DePuy Synthes, Inc.;
DePuy Synthes Sales, Inc.

(hereinafter referred to as “DePuy”) and Johnson & Johnson

(hereinafter, collectively referred to as “Defendants”), pursuant to 5 M.R.S. § 209 of the Maine
Unfair Trade Practices Act (the “UTPA,” 5 M-R-S. §§ 205-A through 214). The Parties have
consented to the entry of this Consent Judgment (“Judgment”) for the purposes of settlement
only, without any admission by any party, and without trial or finding of any issue of fact or law.
PARTIES

1.

The State of Maine is the Plaintiff in this case, acting by and through its Attorney

General Aaron M. Frey who is charged with, among other things, the responsibility of enforcing
5 M.R.S. § 207 of the UTPA.
1

2.

Medical Device Business Services, Inc., f/k/a DePuy Inc., DePuy Orthopedics,

Inc., and DePuy Orthopaedics, Inc., is a Defendant in this case and is an Indiana company, with
executive offices located at 700 Orthopaedic Drive, Warsaw, Indiana 46582.
3.

DePuy Products, Inc. is a Defendant in this case and is an Indiana company, with

executive offices located at 700 Orthopaedic Drive, Warsaw, Indiana 46582.
4.

DePuy Synthes, Inc. is a Defendant in this case and is a Delaware company, with

executive offices located at 700 Orthopaedic Drive, Warsaw, Indiana 46582.
5.

DePuy Synthes Sales, Inc. is a Defendant in this case and is a Massachusetts

company, with executive offices located at 325 Paramount Drive, Raynham, Massachusetts
02767.
6.

DePuy does business in the State of Maine and, at all times relevant hereto,

engaged in trade affecting consumers, within the meaning of 5 M.R.S. § 206 of the UTPA.
7.

Johnson & Johnson is a Defendant in this case and is a New Jersey company, with

executive offices located at One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933.
8.

Johnson & Johnson consents to the jurisdiction of the Court solely for purposes of

this Judgment.
NOW THEREFORE, IT IS HEREBY ORDERED, ADJUDGED AND DECREED
AS FOLLOWS:
I.

FINDINGS

A.

This Court has jurisdiction over the subject matter of this lawsuit and over the

B.

The terms of this Judgment shall be governed by the laws of the State of Maine.

C.

Entry of this Judgment is in the public interest and reflects a negotiated settlement

Parties.

among the Parties.
2

D.

The Parties have agreed to resolve and settle the issues resulting from the Covered

Conduct (defined below) by entering into this Judgment.1
E.

Defendants are willing to enter into this Judgment regarding the Covered Conduct

in order to resolve the Signatory Attorney General’s concerns under the State Consumer
Protection law as to the matters addressed in this Judgment and thereby avoid significant
expense, inconvenience, and uncertainty.
F.

Defendants are entering into this Judgment solely for the purpose of settlement,

and nothing contained herein may be taken as or construed to be an admission or concession of
any violation of law, rule, or regulation, or of any other matter of fact or law, or of any liability
or wrongdoing, all of which Defendants expressly deny. Defendants do not admit any violation
of the State Consumer Protection Laws set forth in footnote 2,2*5and do not admit any wrongdoing

1 This Judgment is entered into pursuant to and subject to the State Consumer Protection law cited in footnote 2.
2 ALABAMA —Alabama Deceptive Trade Practices Act, Ala. Code § 8-19-1 et seq.; ALASKA - Alaska’s Unfair
Trade Practices and Consumer Protection Act, AS 45.50.471 - 561; ARIZONA - Arizona Consumer Fraud Act,
A.R.S. § 44-1521 et seq.; ARKANSAS - Arkansas Deceptive Trade Practices Act, Ark. Code Ann. § 4-88-101, et
seq.; CALIFORNIA - Bus. & Prof Code §§ 17200 et seq. and 17500 et seq.; COLORADO - Colorado Consumer
Protection Act, Colo. Rev. Stat. § 6-1-101 et seq:, CONNECTICUT - Connecticut Unfair Trade Practices Act,
Com. Gen. Stat. §§ 42-110a et seq.; DELAWARE - Delaware Consumer Fraud A ct and Uniform Deceptive Trade
Practices Act, Del. CODE ANN. tit. 6, §§ 2511 to 2536; DISTRICT OF COLUMBIA - District o f Columbia
Consumer Protection Procedures Act, D.C. Code §§ 28-3901 et seq:, FLORIDA — Florida Deceptive and Unfair
Trade Practices Act, Chapter 501, Part II, Florida Statutes, 501.201 et seq:, GEORGIA — Fair Business Practices
Act, O.C.G.A. § 10-1-390 et seq:, HAWAII - Uniform Deceptive Trade Practice Act, Haw. Rev. Stat. Chpt. 481A
and Monopolies; Restraint of Trade, Haw. Rev. Stat. Chpt. 480; IDAHO - Consumer Protection Act, Idaho Code
Section 48-601 et seq:, ILLINOIS - Consumer Fraud and Deceptive Business Practices Act, 815ILCS 505/1 et seq.
and Uniform Deceptive Trade Practices Act, 815 ILCS 510/1 et seq:, INDIANA - Deceptive Consumer Sales Act,
I.C. §24-5-0.5 et seq:, IO W A -Iow a Consumer Fraud Act, Iowa Code Section 714.16, et seq:, KANSAS -Kansas
Consumer Protection Act, K.S.A. 50-623 et seq:, KENTUCKY - KRS 367.110 et seq:, LOUISIANA - Unfair
Trade-Practices and Consumer Protection Law, LSA-R.S. 51:1401, et seq:, MAINE - Unfair Trade Practices Act,
5 M.R.S. §§ 205-A through 214; MARYLAND - Maryland Consumer Protection Act, Md. Code Ann., Com. Law
§§ 13-101 to 13-501; MASSACHUSETTS - Mass. Gen. Laws c. 93A, §§ 2 and 4; MICHIGAN - Michigan
Consumer Protection Act, MCL § 445.901 et seq:, MINNESOTA — Minnesota Deceptive Trade Practices Act,
Minn. Stat. §§ 325D.43-48; Minnesota False Advertising Act, Minn. Stat. § 325F.67; Minnesota Consumer Fraud
Act, Minn. Stat. §§ 325F.68-694; Minnesota Deceptive Trade Practices Against Senior Citizens or Disabled Persons
Act, Minn. Stat. § 325F.71.; MISSOURI - Merchandising Practices Act, Chapter 407, RSMo. MONTANA - Mont.
Code Ann. § 30-14-101 et seq.; NEBRASKA - Consumer Protection Act, Neb. Rev. Stat. § 59-1601 et seq. and
Uniform Deceptive Trade Practices Act, Neb. Rev. Stat. §§ 87-301 et seq.; NEVADA —Deceptive Trade Practices
Act, Nevada Revised Statutes 598.0903 et seq.; NEW HAMPSHIRE - New Hampshire Consumer Protection Act,
RSA 358-A; NEW MEXICO - New Mexico Unfair Practices Act, NMSA 1978, §§ 57-12-1 to -26 (1967, as
amended through 2009); NEW YORK - General Business Law Art. 22-A, §§ 349-50, and Executive Law § 63(12);
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that was or could have been alleged by any Signatory Attorney General.

No part of this

Judgment, including its statements and commitments, shall constitute evidence of any liability,
fault, or wrongdoing by Defendants. This document and its contents are not intended for use by
any third party for any purpose, including submission to any court for any purpose. The Parties
acknowledge that the payment described herein is not a fine, penalty, or payment in lieu thereof.
G.

This Judgment shall not be construed or used as a waiver or limitation of any

legal right, remedy, or defense otherwise available to Defendants in any action, or of their right
to defend themselves from, or make any arguments in, any private individual, regulatory,
governmental, or class claims or suits relating to the subject matter or terms of this Judgment.
Moreover, the Parties do not intend the terms of this Judgment to limit lawful non-promotional
statements made by DePuy and Johnson & Johnson regarding products which are the subject of
the Covered Conduct. This Judgment is made without trial or adjudication of any issue of fact or
law, or finding of liability of any kind. Notwithstanding the foregoing, the State of Maine may
file an action to enforce the terms of this Judgment.
H.

It is the intent of the Parties that this Judgment not be admissible in other cases or

binding on Defendants in any respect other than in connection with the enforcement of this
Judgment.

NORTH CAROLINA — North Carolina Unfair and Deceptive Trade Practices Act, N.C.G.S. §§ 75-1.1, et seq.;
NORTH DAKOTA — Unlawful Sales or Advertising Practices, N.D. Cent. Code § 51-15-02 et seq.; OHIO - Ohio
Consumer Sales Practices Act, R.C. 1345.01, et seq.; OKLAHOMA - Oklahoma Consumer Protection Act 15 O.S.
§§ 751 et seq.; PENNSYLVANIA - Pennsylvania Unfair Trade Practices and Consumer Protection Law, 73 P.S.
201-1 et seq.; RHODE ISLAND - Rhode Island Deceptive Trade Practices Act, Rhode Island General Laws § 613.1-1, et seq.; SOUTH CAROLINA - South Carolina Unfair Trade Practices Act, S.C. Code §§ 39-5-10 et seq.;
SOUTH DAKOTA — South Dakota Deceptive Trade Practices and Consumer Protection, SDCL ch. 37-24;
TENNESSEE - Tennessee Consumer Protection Act, Tenn. Code Ann. § 47-18-101 et seq.; TEXAS - Texas
Deceptive Trade Practices-Consumer Protection Act, Tex. Bus. And Com. Code 17.41, et seq.; UTAH - Utah
Consumer Sales Practices Act, Utah Code § 13-11-1, et seq.; VERMONT - Consumer Protection Act, 9 V.S.A. §§
2451 et seq.; VIRGINIA - Virginia Consumer Protection Act, Va. Code Ann. §§ 59.1-196 through 59.1-207;
WASHINGTON — Unfair Business Practices/Consumer Protection Act, RCW §§ 19.86 et seq.; WISCONSIN Wis. Stat. § 100.18(1) (Fraudulent Representations).
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I.

No part of this Judgment shall create a private cause of action or confer any right

to any third party for violation of any federal or state statute except that the State of Maine may
file an action to enforce the terms of this Judgment.
J.

This Judgment (or any portion thereof) shall in no way be construed to prohibit

Defendants from making representations with respect to any DePuy Product that are permitted
by Federal law or regulation, or in Food and Drug Administration (“FDA”) approved Labeling
for the device under the most current draft or final standard promulgated by the FDA or the most
current draft or final FDA Guidance for Industry, so long as the representation, taken in its
entirety, is not false, misleading, or deceptive.

Nothing in this Judgment shall prohibit

Defendants from revising their procedures and policies to be consistent with then current Federal
law under the Food, Drug and Cosmetic Act, 21 U.S.C. § 301 et seq, (“FDCA”), FDCA
regulations, FDA Guidance, other FDA interpretations or amendments thereto, as it relates to
medical devices.
K.

Nothing in this Judgment shall:
1.

Require Defendants to take any action that is prohibited by the FDCA or

any regulation promulgated thereunder, or by the FDA; or
2.

Require Defendants to fail to take any action that is required by the FDCA

or any regulation promulgated thereunder, or by the FDA, unless facts are or
become known to Defendants that cause the claim to be false, misleading, or
deceptive; or
3.

Preclude Defendants from providing health care economic information to

a formulary committee or similar entity or its members in the course of the
committee or entity carrying out its responsibilities for the selection of medical

5

devices for managed care or other similar organizations pursuant to the applicable
standards of Section 114 of the Food and Drug Administration Modernization Act
of 1997 (“FDAMA”), as it may be amended or revised.
II.

DEFINITIONS

The following definitions shall be used in construing this Judgment:
A.

“Clearly and Conspicuously” shall mean a disclosure in size, color, contrast, font,

and location that is readily noticeable, readable and understandable and is presented in proximity
to all information necessary to prevent it from being misleading or deceptive. A statement may
not contradict or be inconsistent with any other information with which it is presented. If a
statement modifies, explains, or clarifies other information or is necessary to prevent other
information from being misleading or deceptive, that the statement must be presented in close
proximity to that information, in a manner that is readily noticeable, readable, and
understandable, and it must not be obscured in any manner.
B.

“Covered Conduct” shall mean Promotional practices and dissemination of

information regarding the ASR XL Acetabular, ASR Hip Resurfacing, and Pinnacle Ultamet
metal-on-metal hip replacement systems, or any parts thereof.
C.

“Defendants’ Scientifically Trained Personnel” shall mean Defendants’ personnel

who are highly trained experts with specialized scientific or medical knowledge whose roles
involve the provision of specialized, medical or scientific information, scientific analysis and/or
scientific information, but excludes Defendants’ personnel who perform sales, marketing, or
other primarily commercial roles.
D.

“DePuy” shall mean Medical Device Business Services, Inc., f/k/a DePuy Inc.,

DePuy Orthopedics, Inc., and DePuy Orthopaedics, Inc.; DePuy Products, Inc.; DePuy Synthes,
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Inc.; and DePuy Synth Sales, Inc., including all of their predecessors, subsidiaries, successors,
and assigns, and each and all of their current and former officers, directors, shareholders,
employees, agents, responsible for manufacturing, selling, offering for sale, marketing,
Promoting, or distributing any DePuy Product in the United States.

This term shall also

encompass any contractor responsible for marketing or Promoting any DePuy Product in the
United States.
E.

“DePuy Marketing” shall mean DePuy personnel responsible for marketing any

DePuy Product (defined below) in the United States.
F.

“DePuy Product” or “DePuy Products” or “Product(s)” shall mean any hip

replacement system, including its individual components, manufactured and/or Promoted by
DePuy or DePuy Sales (defined below).
G.

“DePuy Sales” shall mean DePuy and third-party personnel responsible for

Promoting (defined below) DePuy Products in the United States.
H.

“Effective Date” shall mean the date on which a copy of this Judgment, duly

executed by Defendants and by the Signatory Attorney General, is approved by, and becomes a
Judgment of the Court and Defendants have been notified via e-mail or regular U.S. mail that all
the Parties hereto have fully executed the Judgment.
I.

“Health Care Professional” or “HCP” shall mean any U.S.-based physician or

other health care practitioner who is licensed to provide health care services or to recommend hip
replacement systems.
J.

“Johnson & Johnson” shall mean Johnson & Johnson, including all its

predecessors, subsidiaries, successors, and assigns, and each and all of their current and former
officers, directors, shareholders, employees, and agents, doing business in the United States.
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This term shall also encompass any contractor responsible for marketing or Promoting any
DePuy Product in the United States.
K.

“Multistate Executive Committee” shall mean the Attorneys General and their

staff representing Florida, Indiana, North Carolina, Ohio, Pennsylvania, South Carolina, Texas,
and Washington.
L.

“Multistate Working Group” shall mean the Attorneys General and their staff

representing Alabama, Arkansas, Alaska, Arizona, California, Colorado, Connecticut, Delaware,
Florida, Georgia, Hawaii, Iowa, Idaho, Illinois, Indiana, Kansas, Kentucky, Louisiana, Maine,
Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New
Hampshire, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma,
Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Vermont,
Virginia, Washington, Wisconsin, Utah, and the District of Columbia.
M.

“Parties” shall mean Defendants and the Signatory Attorney General

N.

“Promotional,” “Promoting,” “Promote,” or “Promoted” shall refer to any

representation about a DePuy Product intended to influence sales of that product, including
attempts to influence Health Care Professional practices for recommending and utilizing that
product, which would be deemed promotional labeling or advertising under the FDCA or any
regulation promulgated thereunder, or by the FDA, under the most current draft or final standard
promulgated by the FDA or the most current draft or final FDA Guidance for Industry.
O.

“Signatory Attorney General” shall mean the Attorney General of Maine, or his

authorized designee, who has agreed to this Judgment.
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P.

“Sponsor” or “Sponsorship” or “Sponsored” shall mean to pay or have paid in

whole or in part, to provide or have provided financial support or subsidization, or to provide or
have provided goods or materials of value in support of more than de minimis value.
Q.

“State Consumer Protection Laws” shall mean the consumer protection law(s)

under which the Signatory Attorney General has conducted his investigation.3
HI.

COMPLIANCE PROVISIONS

1. General Provision:

A.

In Promoting a DePuy Product, DePuy shall not violate 5 M.R.S. § 207 of

Maine’s UTPA listed in footnote 2.
2. Specific Provisions:

The following subsections of Section III shall be effective for five years from the
Effective Date of this Judgment.
A.

In Promoting a DePuy Product, any representations by DePuy about implant

wear, survivorship, stability, or dislocations of any DePuy Product or component part of a DePuy
Product shall be based on information approved by Scientifically Trained Personnel as relevant,
shall cite to the source of the information consistent with all guidelines for citation promulgated
by the information source, and shall expressly disclose if DePuy Sponsored or otherwise funded
the study that generated the cited information consistent with Section III(2)(C) below. Where
such Promotions utilize registry data, DePuy shall use the most recent dataset available from the
registry at the time the Promotional material is approved for distribution, and shall notate on the
Promotional material the registry sources and dates utilized.

3 The Maine Unfair Trade Practices Act, 5 M.R.S. §§ 205-A through 214.
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B.

When submitting or publishing a study, manuscript, or abstract, DePuy shall

follow its practice of following the most recent Recommendations for the Conduct, Reporting,
Editing, and Publication o f Scholarly Work in Medical Journals developed by the International
Committee of Medical Journal Editors (“ICMJE”) guidelines for the naming of authors.
C.

In all DePuy-Sponsored manuscripts reporting the results of a DePuy-Sponsored

study, DePuy shall comply with its policy of disclosing DePuy’s role as a Sponsor, and any
author’s potential conflict of interest, consistent with the disclosure requirements of the ICMJE.
D.

In any materials used to Promote any DePuy Product including, but not limited to,

abstracts, posters, brochures, and direct-to-consumer marketing advertisements, whether
distributed in hard copy, digital, or electronic format, in which information is derived primarily
from a study that has been designed or Sponsored by DePuy, DePuy shall Clearly and
Conspicuously identify itself as the Sponsor of the study. This provision shall not apply to
communications or materials that are only used internally by DePuy. Any such communications
or materials that are used internally by DePuy that do not Clearly and Conspicuously identify
DePuy as the Sponsor of a study shall not be used to market or Promote any DePuy Product.
E.

DePuy shall, when citing to any clinical study, clinical data, or preclinical data in

any materials used to Promote any DePuy Product:
1.

Present in accordance with applicable FDA guidance a fair balance of

available scientific literature with respect to the safety, efficacy, risks, and
complications of DePuy Products;
2.

Present favorable information or conclusions only from studies that

DePuy’s Scientifically Trained Personnel determine to have clinical significance
or validity in terms of study design, scope, and conduct;
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3.

Use only data that DePuy’s Scientifically Trained Personnel determine to

have clinical significance or validity, and use such data only in a manner
approved by DePuy’s Scientifically Trained Personnel’s prior to the distribution
of Promotional materials.
F.

DePuy shall update as warranted, and maintain a post market surveillance

program that provides for a comprehensive review and analysis of Product performance and
safety information, and a Product complaint handling program that promotes compliance with
Product complaint handling and medical device reporting regulations and requirements
including, but not limited to, what is currently titled 21 CFR Part 803 and relevant FDA
Guidance documents.
G.

DePuy shall update as warranted, and maintain internal Product complaint

handling operating procedures and guidance that provide clear instruction, comply with
applicable regulations, and define terms consistent with applicable FDA definitions of those
terms. Any DePuy employee whose responsibilities include complaint handling shall review the
operating procedures and guidance and be trained on them.
H.

DePuy shall update as warranted, and maintain processes and procedures to track

and analyze Product complaints, including those that do not meet the definition of Medical
Device Reportable Event under applicable regulations, have more than one cause, or present
more than one symptom or issue.
I.

DePuy shall comply with any and all federal requirements regarding the reporting

of any Medical Device Reportable Event associated with any DePuy Product, and shall report
any such event from any source to the FDA as required under the Mandatory Device Reporting
regulation (21 CFR 803).
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J.

DePuy shall maintain a quality assurance program that includes an audit

procedure for tracking complaints regarding DePuy Products that do not rise to the level of a
Medical Device Reportable Event, but which may indicate a device-related serious-injury or
malfunction.
K.

DePuy shall perform at least quarterly reviews of complaints, and where any

clearly identifiable and definable sub-group of the patient population has a higher incidence of
adverse events or Medical Device Reportable Events than the rest of the patient population
indicating a potential safety signal, DePuy shall: (1) take good faith measures to determine the
cause, if any, of a higher incidence; and (2) communicate findings to DePuy Marketing and
engage in good faith discussions regarding whether such findings should alter Promotional
practices that may Promote the Product to the portion or group of the patient population in
question.

In the event that DePuy determines that such findings should alter Promotional

practices, DePuy shall notify Health Care Professionals accordingly, either in person or via Dear
Doctor letters.
L.

DePuy shall not represent or imply that Plaintiff or the Signatory Attorney

General acquiesces in or approves of DePuy’s past or current business practices, its efforts to
reform its practices, or any future practices that DePuy may adopt or consider adopting.
IV.

PAYMENT

No later than 30 days after the Effective Date of this Judgment, Defendants shall pay a
total amount of $120,000,000.00 (One Hundred Twenty Million Dollars) to be divided and paid
by Defendants directly to each Attorney General of the Multistate Working Group in an amount
to be designated by and in the sole discretion of the Multistate Executive Committee.4 Said

4 The payment to the Signatory Attorney General under this section shall be $1,408,746.95.
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payment shall be used by the States as attorneys’ fees and other costs of investigation and
litigation, or to be placed in, or applied to, consumer protection enforcement funds, including
future consumer protection enforcement, consumer education, litigation or local consumer aid
fund or revolving fund, used to defray the costs of the inquiry leading hereto, or for any lawful
purpose, at the sole discretion of each Attorney General of the Multistate Working Group.
V.

A.

RELEASE

By its execution of this Judgment, the State of Maine releases and forever

discharges Defendants (the “Released Parties”) from the following: all civil claims, causes of
action, damages, restitution, disgorgement, fines, costs, attorneys’ fees, remedies, and/or
penalties that the Signatory Attorney General has asserted, or could have asserted, against the
Released Parties under Maine’s UTPA, or any amendments thereto, or by common law claims
concerning unfair, deceptive, or fraudulent trade practices or, if applicable, state statutes
equivalent to the FDCA that the Signatory Attorney General has the authority to release resulting
from the Covered Conduct up to and including the Effective Date that is the subject of the
Judgment.
B.

Notwithstanding any term of this Judgment, specifically reserved and excluded

from the release in Section V(A) as to any entity or person, including Released Parties, are any
and all of the following:
1.

Any criminal liability that any person and/or entity, including Released Parties,

has or may have to the State of Maine.
2.

Any civil or administrative liability that any person and/or entity, including

Released Parties, has or may have to the State of Maine not expressly covered by the
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release in Section V(A) above including, but not limited to, any and all of the following
claims:
a.

State or federal antitrust violations;

b.

Claims involving “best price,” “average wholesale price,” “wholesale
acquisition cost,” or any reporting practices;

c.

Medicaid claims, including, but not limited to, federal Medicaid drug
rebate statute violations, Medicaid fraud or abuse, and/or kickback
violations related to any State’s Medicaid program;

d.

State false claims violations; and

e.

Actions of state program payors of the State of Maine arising from the
purchase of a DePuy Product.

3.

Any claims individual consumers, including classes of consumers bringing class

actions, have or may have under the State of Maine’s above-cited consumer protection
law, and any common law claims individual consumers, including classes of consumers
bringing class actions, may have concerning unfair, fraudulent or deceptive trade
practices against any person and/or entity, including Released Parties.
VI.

A.

DISPUTE RESOLUTION

For the purposes of resolving disputes with respect to compliance with this

Judgment, should the Signatory Attorney General have a reasonable basis to believe that
Defendants have violated, or are violating, any provision of this Judgment subsequent to the
Effective Date, then the Signatory Attorney General shall notify Defendants in writing of the
specific objection, identify with particularity the provisions of this Judgment that the practice
appears to violate, and give Defendants 30 days to respond to the notification.

14

B.

Upon receipt of written notice from the Signatory Attorney General, Defendants

shall provide a good-faith written response to the Signatory Attorney General’s notification,
containing either a statement explaining why Defendants believe they are in compliance with the
Judgment, or a detailed explanation of how the alleged violation occurred and a statement
explaining how and when Defendants intend to remedy the alleged violation.
C.

Except as set forth in Sections VI(D) and (E) below, the Signatory Attorney

General may not take any action concerning the alleged violation of this Judgment during the 30day response period. Nothing shall prevent the Signatory Attorney General from agreeing in
writing to provide Defendants with additional time beyond the 30 days to respond to the notice.
D.

Nothing in this Judgment shall be interpreted to limit the State’s investigative

subpoena authority, to the extent such authority exists under applicable state law, and Defendants
reserve all their rights in responding to an investigative subpoena issued pursuant to such
authority.
E.

The Signatory Attorney General may assert any claim that Defendants have

violated this Judgment in a separate civil action to enforce compliance with this Judgment, or
may seek any other relief afforded by law for violations of the Judgment, but only after
providing Defendants an opportunity to respond to the notification as described above and to
remedy, to the satisfaction of the Signatory Attorney General, the alleged violation within the 30day response period as described above, or within any other period as agreed to by Defendants
and the Signatory Attorney General. Elowever, the Signatory Attorney General may take any
action including, but not limited to, legal action to enforce compliance with the Judgment,
without delay if the Signatory Attorney General believes that, because of the specific practice, a
threat to the health or safety of the public requires immediate action.
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VII.

A.

GENERAL PROVISIONS

Defendants shall not knowingly permit, cause, or encourage third parties acting

on their behalf, to engage in practices from which Defendants are prohibited by this Judgment.
B.

This Judgment does not constitute an approval by the Signatory Attorney General

of Defendants’ business practices, and Defendants shall make no representation or claim to the
contrary.
C.

Any failure by any party to this Judgment to insist upon the strict performance by

any other party of any of the provisions of this Judgment shall not be deemed a waiver of any of
the provisions of this Judgment, and such party, notwithstanding such failure, shall have the right
thereafter to insist upon the specific performance of any and all of the provisions of this
Judgment.
D.

This Judgment represents the full and complete terms of the settlement entered

into by the Parties hereto. The Parties acknowledge that no other promises, representations, or
agreements of any nature have been made or entered into by the Parties. The Parties further
acknowledge that this Judgment constitutes a single and entire agreement that is not severable or
divisible, except that if any provision herein is found to be legally insufficient or unenforceable,
the remaining provisions shall continue in full force and effect. In any action undertaken by the
Parties, no prior versions of this Judgment and no prior versions of any of its terms that were not
entered by the Court in this Judgment may be introduced for any purpose whatsoever.
E

This Court retains jurisdiction of this Judgment and the Parties hereto for the

purpose of enforcing and modifying this Judgment and for the purpose of granting such
additional relief as may be necessary and appropriate
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F.

The Judgment may be modified by a stipulation of the Parties once it is approved

by, and becomes a judgment of the Court, or by court proceedings resulting in a modification of
the Judgment by the Court.
G.

In the event any law or regulation is enacted or adopted by the federal government

or by the State of Maine, and the requirements of such law or regulation create a conflict with
any terms of this Judgment, Defendants shall notify the Attorney General in writing as to the
extent of the conflict. If the Attorney General agrees, he shall consent to a modification of such
provision of the Judgment to the extent necessary to eliminate such conflict. If the Attorney
General disagrees and the Parties are not able to resolve the disagreement, Defendants may seek
a modification from this Court of any provision of this Judgment that presents a conflict with any
such federal or state law or regulation. Changes in federal or state laws or regulations, with
respect to the matters governed by this Judgment, shall not be deemed to create a conflict with a
provision of this Consent Judgment unless Defendants cannot reasonably comply with both such
law or regulation and the applicable provision of this Judgment.
H.

This Judgment may be executed in counterparts, and a facsimile or .pdf signature

shall be deemed to be, and shall have the same force and effect as, an original signature.
I.

All Notices under this Judgment shall be provided to the following via e-mail and

Overnight Mail:
For Defendants:
William Craco
Johnson & Johnson Law Department
One Johnson & Johnson Plaza
New Brunswick, NJ 08933
wcraco@its.jnj.com
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Ross B. Galin
O’Melveny & Myers LLP
Times Square Tower
7 Times Square
New York, NY 10036
rgalin@omm.com
Notice shall also be provided to any person subsequently designated by Defendants to receive
such notice of failure to comply.
For the State of Maine:
Linda J. Conti, Assistant Attorney General
Chief, Consumer Protection Division
Office of the Maine Attorney General
Burton Cross Office Building
111 Sewall Street, 6th Floor
Augusta, ME 04330
linda. conti@maine .gov
J.

To the extent that any provision of this Judgment obligates Defendants to change

any policy(ies) or procedure(s) and to the extent not already accomplished, Defendants shall
implement the policy(ies) or procedure(s) as soon as reasonably practicable but no later than 120
days after the Effective Date of this Judgment.

Dated:
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Plaintiff State of Maine:

AARON M. FREY
ATTORNEY GENERAL*6

Date:

!j Z Z - / / ^
Carolyn A. Silsby,
Assistant Attorney
Office of the Maine Attorney General
6 State House Station
Augusta, ME 04333-0006
(207)626-8800
Carolyn.silsby@maine.gov
Counsel for Plaintiff

Defendant Johnson & Johnson:

Date:
Name
Title

Defendant Medical Device Business Services, Inc., f/k/a DePuy Inc. DePuy Orthopedics,
Inc., and DePuy Orthopaedics, Inc.

Date:
Name
Title

Defendant DePuy Products, Inc.

Date:

By:
Name
Title
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Defendant Johnson & Johnson:

Defendant Medical Device Business Services, Inc., f/k/a DePuy Inc. and DePuy Orthopaedics,
Inc.

Date: 11

Defendant DePuy Products, Inc.

Date;

l o / n

Defendant DePuy Synthes, Inc,

Date: ^

i u [ ñ

Defendant DePuy Synth Sales, Inc.

Date:

// /

(jj / ^

By:
Tina French J
Assisf|nti3<5rporate Secretary

Approved as to form:
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V

Date:

Date:

i m j Z o i ci

By:
r o s s b . g a L in

7
STEVE BRODY
O’Melveny & Myers LLP
Times Square Tower
7 Times Square
New-York, NY 10036
By: _____ ;_____ _
[Local Counsel]

Counsel for Defendants
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Date:

ROSSB. GALIN
STEVE BRODY
O’Melveny & Myers LLP
Times Square Tower
7 Times Square
New York, NY 10036

D ate:

'hJiq

By:
iSM. CAMPBELL (ME BAR #3551)
p b e l l C o n r o y & O ’N e il , P.C.
1 Constitution Wharf, Suite 310
Boston, MA 02129
P: 617-241-3000
F: 617-241-5115
Email: imcampbell@camnbell-trial-lawvers.com

Counselfo r Defendants
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